Malformations of cortical development represent a common cause of epileptic encephalopathies and drug-resistant epilepsy in children. As current treatments are often ineffective, new therapeutic targets are needed for epileptic encephalopathies associated with cortical malformations. The mechanistic/mammalian target of rapamycin (mTOR) pathway constitutes a signaling pathway that drives cellular and molecular mechanisms of epileptogenesis in a variety of focal cortical malformations. mTOR inhibitors prevent epilepsy and associated pathogenic mechanisms of epileptogenesis in mouse models of tuberous sclerosis complex and are currently in clinical trials for drug-resistant seizures in these patients. A recent explosion of genetic studies has linked mutations in various genes regulating the mTOR pathway to other cortical malformations, such as focal cortical dysplasia and hemimegalencephaly. Thus, mTOR inhibitors represent promising candidates as novel antiseizure and antiepileptogenic therapies for epilepsy associated with a spectrum of cortical malformations.
EngelJJr. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia. 2001;42(6):796–803.
2.
BergATBerkovicSFBrodieMJ. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia. 2010;51(4):676–685.
3.
McTagueAHowellKBCrossJHKurianMASchefferIE. The genetic landscape of the epileptic encephalopathies of infancy and childhood. Lancet Neurol. 2016;15(3):304–316.
4.
YamatogiYOhtaharaS. Early-infantile epileptic encephalopathy with suppression-bursts, Ohtahara syndrome; its overview referring to our 16 cases. Brain Dev. 2002;24(1):13–23.
5.
OhtaharaSITOkaEYamatogiYInoueH. On the specific age dependent epileptic syndrome: the early-infantile epileptic encephalopathy with suppression-burst (in Japanese). No To Hattatsu (Tokyo). 1976;8:270–280.
6.
OgiharaMKinoueKTakamiyaH. A case of early infantile epileptic encephalopathy (EIEE) with anatomical cerebral asymmetry and myoclonus. Brain Dev. 1993;15(2):133–139.
7.
BermejoAMMartinVLArcasJPerez-HiguerasAMoralesCPascual-CastroviejoI. Early infantile epileptic encephalopathy: a case associated with hemimegalencephaly. Brain Dev. 1992;14(6):425–428.
8.
PedespanJMLoiseauHVitalAMarchalCFontanDRougierA. Surgical treatment of an early epileptic encephalopathy with suppression-bursts and focal cortical dysplasia. Epilepsia. 1995;36(1):37–40.
9.
KomakiHSugaiKSasakiM. Surgical treatment of a case of early infantile epileptic encephalopathy with suppression-bursts associated with focal cortical dysplasia. Epilepsia. 1999;40(3):365–369.
10.
NabboutRDulacO. Epileptic encephalopathies: a brief overview. J Clin Neurophysiol. 2003;20(6):393–397.
PanayiotopoulosC. The Epilepsies: Seizures, Syndromes and Management. Oxfordshire, UK: Bladon; 2005.
13.
OsborneJPLuxALEdwardsSW. The underlying etiology of infantile spasms (West syndrome): information from the United Kingdom Infantile Spasms Study (UKISS) on contemporary causes and their classification. Epilepsia. 2010;51(10):2168–2174.
14.
GoCYMackayMTWeissSK. Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2012;78(24):1974–1980.
15.
ChuganiHTShewmonDAShieldsWD. Surgery for intractable infantile spasms: neuroimaging perspectives. Epilepsia. 1993;34(4):764–771.
16.
DulacOPlouinPJambaqueI. Predicting favorable outcome in idiopathic West syndrome. Epilepsia. 1993;34(4):747–756.
17.
LuxALEdwardsSWHancockE. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol. 2005;4(11):712–717.
18.
Chu-ShoreCJMajorPCamposanoSMuzykewiczDThieleEA. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia. 2010;51(7):1236–1241.
19.
TrevathanEMurphyCCYeargin-AllsoppM. The descriptive epidemiology of infantile spasms among Atlanta children. Epilepsia. 1999;40(6):748–751.
20.
GuerriniRCarrozzoR. Epilepsy and genetic malformations of the cerebral cortex. Am J Med Genet. 2001;106(2):160–173.
21.
YouSJLeeJKKoTS. Epilepsy surgery in a patient with Lennox-Gastaut syndrome and cortical dysplasia. Brain Dev. 2007;29(3):167–170.
22.
CamfieldPR. Definition and natural history of Lennox-Gastaut syndrome. Epilepsia. 2011;52(suppl 5):3–9.
23.
PasquierBPeoc’hMFabre-BocquentinB. Surgical pathology of drug-resistant partial epilepsy. A 10-year-experience with a series of 327 consecutive resections. Epileptic Disord. 2002;4(2):99–119.
24.
BarkovichAJGuerriniRKuznieckyRIJacksonGDDobynsWB. A developmental and genetic classification for malformations of cortical development: update 2012. Brain. 2012;135(pt 5):1348–1369.
25.
European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75(7):1305–1315.
26.
van SlegtenhorstMde HoogtRHermansC. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997;277(5327):805–808.
27.
CrinoPBNathansonKLHenskeEP. The tuberous sclerosis complex. N Engl J Med. 2006;355(13):1345–1356.
28.
DiMarioFJJrSahinMEbrahimi-FakhariD. Tuberous sclerosis complex. Pediatr Clin North Am. 2015;62(3):633–648.
PuffenbergerEGStraussKARamseyKE. Polyhydramnios, megalencephaly and symptomatic epilepsy caused by a homozygous 7-kilobase deletion in LYK5. Brain. 2007;130(pt 7):1929–1941.
39.
Flores-SarnatL. Hemimegalencephaly: part 1. Genetic, clinical, and imaging aspects. J Child Neurol. 2002;17(5):373–384; discussion 384.
40.
Flores-SarnatLSarnatHBDavila-GutierrezGAlvarezA. Hemimegalencephaly: part 2. Neuropathology suggests a disorder of cellular lineage. J Child Neurol. 2003;18(11):776–785.
FauserSHuppertzHJBastT. Clinical characteristics in focal cortical dysplasia: a retrospective evaluation in a series of 120 patients. Brain. 2006;129(pt 7):1907–1916.
43.
BlumckeIThomMAronicaE. The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. Epilepsia. 2011;52(1):158–174.
44.
PalminiANajmIAvanziniG. Terminology and classification of the cortical dysplasias. Neurology. 2004;62(6 suppl 3): S2–S8.
45.
ShorvonSD. Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959-2009. Epilepsia. 2009;50(suppl 3):93–130.
46.
BaulacSIshidaSMarsanE. Familial focal epilepsy with focal cortical dysplasia due to DEPDC5 mutations. Ann Neurol. 2015;77(4):675–683.
LeeJHHuynhMSilhavyJL. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. Nat Genet. 2012;44(8):941–945.
49.
OrlovaKAParkerWEHeuerGG. STRADalpha deficiency results in aberrant mTORC1 signaling during corticogenesis in humans and mice. J Clin Invest. 2010;120(5):1591–1602.
50.
LaplanteMSabatiniDM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274–293.
51.
LiptonJOSahinM. The neurology of mTOR. Neuron. 2014;84(2):275–291.
52.
ZoncuREfeyanASabatiniDM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12(1):21–35.
53.
TeeARManningBDRouxPPCantleyLCBlenisJ. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol. 2003;13(15):1259–1268.
54.
InokiKLiYZhuTWuJGuanKL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002;4(9):648–657.
55.
GwinnDMShackelfordDBEganDF. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 2008;30(2):214–226.
56.
Bar-PeledLChantranupongLCherniackAD. A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science. 2013;340(6136):1100–1106.
57.
KruegerDACareMMHollandK. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. New Engl J Med. 2010;363(19):1801–1811.
58.
BisslerJJKingswoodJCRadzikowskaE. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9869):817–824.
59.
McCormackFXInoueYMossJ. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364(17):1595–1606.
60.
WongM. Mechanisms of epileptogenesis in tuberous sclerosis complex and related malformations of cortical development with abnormal glioneuronal proliferation. Epilepsia. 2008;49(1):8–21.
61.
WongM. A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trials. Expert Rev Neurother. 2013;13(6):657–669.
62.
GotoJTalosDMKleinP. Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex. Proc Natl Acad Sci USA. 2011;108(45): E1070–E1079.
63.
CarsonRPVan NielenDLWinzenburgerPAEssKC. Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin. Neurobiol Dis. 2012;45(1):369–380.
64.
MeikleLPollizziKEgnorA. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci. 2008;28(21):5422–5432.
65.
ZengLHXuLGutmannDHWongM. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol. 2008;63(4):444–453.
66.
ZengLHRensingNRZhangBGutmannDHGambelloMJWongM. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex. Hum Mol Genet. 2011;20(3):445–454.
67.
GalanopoulouASBuckmasterPSStaleyKJ. Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia. 2012;53(3):571–582.
68.
KruegerDAWilfongAAHolland-BouleyK. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol. 2013;74(5):679–687.
69.
CardamoneMFlanaganDMowatDKennedySEChopraMLawsonJA. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex. J Pediatr. 2014;164(5):1195–1200.
70.
JeongAWongM. Tuberous sclerosis complex as a model disease for developing new therapeutics for epilepsy. Expert Rev Neurother. 2016;16(4):437–447.
71.
DattaANHahnCDSahinM. Clinical presentation and diagnosis of tuberous sclerosis complex in infancy. J Child Neurol. 2008;23(3):268–273.
72.
WuJYPetersJMGoyalM. Clinical electroencephalographic biomarker for impending epilepsy in asymptomatic tuberous sclerosis complex infants. Pediatr Neurol. 2016;54:29–34.
73.
CrinoPB. Focal brain malformations: a spectrum of disorders along the mTOR cascade. Novartis Found Symp. 2007;288:260–272; discussion 272-281.
74.
BaybisMYuJLeeA. mTOR cascade activation distinguishes tubers from focal cortical dysplasia. Ann Neurol. 2004;56(4):478–487.
75.
LjungbergMCBhattacharjeeMBLuY. Activation of mammalian target of rapamycin in cytomegalic neurons of human cortical dysplasia. Ann Neurol. 2006;60(4):420–429.
76.
D’GamaAMGengYCoutoJA. Mammalian target of rapamycin pathway mutations cause hemimegalencephaly and focal cortical dysplasia. Ann Neurol. 2015;77(4):720–725.
77.
ParkerWEOrlovaKAParkerWH. Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder. Sci Transl Med. 2013;5(182):182ra53.
78.
ScerriTRiseleyJRGilliesG. Familial cortical dysplasia type IIA caused by a germline mutation in DEPDC5. Ann Clin Transl Neurol. 2015;2(5):575–580.
79.
NakashimaMSaitsuHTakeiN. Somatic mutations in the MTOR gene cause focal cortical dysplasia type IIb. Ann Neurol. 2015;78(3):375–386.
80.
CheungKMLamCWChanYKSiuWKYongL. Atypical focal cortical dysplasia in a patient with Cowden syndrome. Hong Kong Med J. 2014;20(2):165–167.
81.
BackmanSAStambolicVSuzukiA. Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nat Genet. 2001;29(4):396–403.
82.
KwonCHZhuXZhangJBakerSJ. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc Natl Acad Sci USA. 2003;100(22):12923–12928.
83.
LjungbergMCSunnenCNLugoJNAndersonAED’ArcangeloG. Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia. Dis Model Mech. 2009;2(7-8):389–398.
84.
SunnenCNBrewsterALLugoJN. Inhibition of the mammalian target of rapamycin blocks epilepsy progression in NS-Pten conditional knockout mice. Epilepsia. 2011;52(11):2065–2075.
85.
RaffoECoppolaAOnoTBriggsSWGalanopoulouAS. A pulse rapamycin therapy for infantile spasms and associated cognitive decline. Neurobiol Dis. 2011;43(2):322–329.
86.
FelicianoDMSuTLopezJPlatelJCBordeyA. Single-cell Tsc1 knockout during corticogenesis generates tuber-like lesions and reduces seizure threshold in mice. J Clin Invest. 2011;121(4):1596–1607.
87.
LimJSKimWIKangHC. Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy. Nat Med. 2015;21(4):395–400.
88.
BaekSTCopelandBYunEJ. An AKT3-FOXG1-reelin network underlies defective migration in human focal malformations of cortical development. Nat Med. 2015;21(12):1445–1454.
